Hybrid imaging for pancreatic malignancy: Clinical applications, merits, limitations, and pitfalls

Priyanka Jha, Bijan Bijan, Giselle M Melendres, David K. Shelton

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The role of PET/CT in pancreatic malignancy is evolving with new scientific evidence emerging continuously. PET/CT applications in imaging the pancreas and its organ-specific merits, limitations, and potential pitfalls are still evolving. This article provides an overview of the state-of-the-art applications of PET/CT imaging in evaluating pancreatic malignancy, comparing with conventional imaging modalities, such as contrast-enhanced CT and MRI. Current PET/MRI is also reviewed, along with brief discussion on cost-benefit analysis.

Original languageEnglish (US)
Pages (from-to)206-213
Number of pages8
JournalClinical Nuclear Medicine
Volume40
Issue number3
DOIs
StatePublished - Mar 13 2015

Fingerprint

Multimodal Imaging
Cost-Benefit Analysis
Pancreas
Neoplasms

Keywords

  • pancreas adenocarcinoma
  • pancreatic adenocarcinoma
  • pancreatic malignancy
  • PET/CT
  • PET/MRI

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Hybrid imaging for pancreatic malignancy : Clinical applications, merits, limitations, and pitfalls. / Jha, Priyanka; Bijan, Bijan; Melendres, Giselle M; Shelton, David K.

In: Clinical Nuclear Medicine, Vol. 40, No. 3, 13.03.2015, p. 206-213.

Research output: Contribution to journalArticle

@article{53052c25041d4067b3c7776a0c5b8a2c,
title = "Hybrid imaging for pancreatic malignancy: Clinical applications, merits, limitations, and pitfalls",
abstract = "The role of PET/CT in pancreatic malignancy is evolving with new scientific evidence emerging continuously. PET/CT applications in imaging the pancreas and its organ-specific merits, limitations, and potential pitfalls are still evolving. This article provides an overview of the state-of-the-art applications of PET/CT imaging in evaluating pancreatic malignancy, comparing with conventional imaging modalities, such as contrast-enhanced CT and MRI. Current PET/MRI is also reviewed, along with brief discussion on cost-benefit analysis.",
keywords = "pancreas adenocarcinoma, pancreatic adenocarcinoma, pancreatic malignancy, PET/CT, PET/MRI",
author = "Priyanka Jha and Bijan Bijan and Melendres, {Giselle M} and Shelton, {David K.}",
year = "2015",
month = "3",
day = "13",
doi = "10.1097/RLU.0000000000000677",
language = "English (US)",
volume = "40",
pages = "206--213",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hybrid imaging for pancreatic malignancy

T2 - Clinical applications, merits, limitations, and pitfalls

AU - Jha, Priyanka

AU - Bijan, Bijan

AU - Melendres, Giselle M

AU - Shelton, David K.

PY - 2015/3/13

Y1 - 2015/3/13

N2 - The role of PET/CT in pancreatic malignancy is evolving with new scientific evidence emerging continuously. PET/CT applications in imaging the pancreas and its organ-specific merits, limitations, and potential pitfalls are still evolving. This article provides an overview of the state-of-the-art applications of PET/CT imaging in evaluating pancreatic malignancy, comparing with conventional imaging modalities, such as contrast-enhanced CT and MRI. Current PET/MRI is also reviewed, along with brief discussion on cost-benefit analysis.

AB - The role of PET/CT in pancreatic malignancy is evolving with new scientific evidence emerging continuously. PET/CT applications in imaging the pancreas and its organ-specific merits, limitations, and potential pitfalls are still evolving. This article provides an overview of the state-of-the-art applications of PET/CT imaging in evaluating pancreatic malignancy, comparing with conventional imaging modalities, such as contrast-enhanced CT and MRI. Current PET/MRI is also reviewed, along with brief discussion on cost-benefit analysis.

KW - pancreas adenocarcinoma

KW - pancreatic adenocarcinoma

KW - pancreatic malignancy

KW - PET/CT

KW - PET/MRI

UR - http://www.scopus.com/inward/record.url?scp=84922652652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922652652&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000677

DO - 10.1097/RLU.0000000000000677

M3 - Article

C2 - 25608151

AN - SCOPUS:84922652652

VL - 40

SP - 206

EP - 213

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 3

ER -